• Spiroplasma eriocheiris Entry: Clathrin-Mediated Endocytosis

  2026-05-15

  This study demonstrates that Spiroplasma eriocheiris invades Drosophila S2 cells primarily through clathrin-mediated endocytosis and macropinocytosis, processes that can be experimentally disrupted with specific inhibitors such as Chlorpromazine HCl. The findings clarify infection mechanisms in invertebrate cell models and highlight methodological avenues for dissecting host-pathogen interactions.

• JNJ-26481585 (Quisinostat): Applied HDAC Inhibition Workflow

  2026-05-15

  JNJ-26481585 (Quisinostat) enables precise epigenetic modulation for robust apoptosis induction and drug resistance reversal in cancer models. This guide translates recent TRIM21 research into actionable experimental workflows, troubleshooting insights, and advanced protocol enhancements for HDAC inhibitor applications.

• PCMT1 Drives Ovarian Cancer Metastasis: Insights from CRISPR

  2026-05-14

  Zhang et al. used a genome-wide CRISPR/Cas9 knockout screen to reveal PCMT1 as a key regulator of anoikis resistance and metastasis in ovarian cancer. Their findings highlight the extracellular interactions of PCMT1 with the ECM and its potential as a therapeutic target, advancing the mechanistic understanding of metastatic progression.

• Toremifene in Prostate Cancer Research: Applied Workflows &

  2026-05-14

  Toremifene, a potent second-generation selective estrogen-receptor modulator, empowers researchers to dissect estrogen and calcium signaling in prostate cancer. This article details stepwise workflows, troubleshooting, and recent mechanistic insights—grounded in peer-reviewed evidence—to drive robust, reproducible results in hormone-responsive cancer models.

• (R,S)-Anatabine: Mechanisms and Evidence in Amyloid Reductio

  2026-05-13

  (R,S)-Anatabine, a minor tobacco alkaloid, inhibits amyloid-beta peptide formation through APP β-cleavage suppression and BACE-1 downregulation. Its activity in both in vitro and in vivo Alzheimer's disease models supports its utility as a neurodegeneration research tool.

• LMO2–LDB1 Complex Drives AML Progression: Mechanisms and Imp

  2026-05-13

  This study uncovers how the interaction between LMO2 and the transcriptional co-regulator LDB1 promotes acute myeloid leukemia (AML) progression. Through knockdown, proteomic, and sequencing approaches, the authors reveal the LMO2/LDB1 complex’s central role in leukemic cell proliferation and survival, providing a foundation for targeted research strategies in hematologic malignancies.

• Angiotensin II in Hypertension Mechanism and Vascular Resear

  2026-05-12

  Angiotensin II (Asp-Arg-Val-Tyr-Ile-His-Pro-Phe) is a gold-standard tool for modeling hypertension and vascular remodeling, offering robust and reproducible workflows for disease mechanism studies and preclinical models. This article delivers actionable strategies, advanced troubleshooting, and protocol enhancements to maximize the translational impact of APExBIO’s Angiotensin II peptide.

• EZ Cap™ Mouse IL-12 mRNA (m1Ψ): Workflow Innovations in Immu

  2026-05-12

  EZ Cap™ Mouse IL-12 mRNA (m1Ψ) empowers extrahepatic cytokine expression with enhanced stability and translational efficiency, unlocking new frontiers in immunotherapy research. This article translates cutting-edge delivery science into actionable protocols, troubleshooting, and comparative insights for mRNA-based immune modulation.

• DAPT (GSI-IX): Advancing Notch Pathway Research in Organoid

  2026-05-11

  Explore how DAPT (GSI-IX) empowers advanced Notch signaling and γ-secretase research in organoid and stem cell models. This article uniquely integrates state-of-the-art organoid methodologies and practical assay guidance, offering deeper scientific insights for translational research.

• Luminescent ATP Detection Assay Kit: Precision for Energy Me

  2026-05-11

  Unlock ultra-sensitive ATP quantification with the Luminescent ATP Detection Assay Kit. This firefly luciferase ATP assay streamlines workflows in inflammation and energy metabolism research—empowering robust, reproducible insights even in challenging cellular and tissue models.

• Strategic MEK1/2 Inhibition: U0126-EtOH in Translational Res

  2026-05-10

  This article explores the mechanistic underpinnings and translational impact of highly selective MEK1/2 inhibition with U0126-EtOH. Addressing neuroprotection, anti-inflammatory strategies, and cancer differentiation models, it draws on rigorous evidence—including landmark studies of MAPK/ERK pathway modulation and the role of ERK1/2 in leukemia cell differentiation. The discussion provides actionable protocol guidance, workflow troubleshooting, and a strategic vision for advancing research outcomes, distinguishing itself from typical product-centric reviews.

• Applied Use-Cases for MK-1775: Wee1 Kinase Inhibitor in DNA

  2026-05-09

  MK-1775 (Wee1 kinase inhibitor) from APExBIO enables precise abrogation of the G2 DNA damage checkpoint, facilitating robust sensitization of p53-deficient tumor cells in both in vitro and in vivo models. By leveraging advanced protocols and troubleshooting strategies, researchers can maximize assay reproducibility and data clarity for next-generation cancer therapeutics.

• Angiotensin II (A1042): Protocols & QC for Vascular Research

  2026-05-08

  Angiotensin II (SKU A1042) addresses the need for a well-characterized, high-purity peptide to model hypertension, vascular smooth muscle cell hypertrophy, and cardiovascular remodeling in controlled research settings. It is not intended for diagnostic or medical use, and users should adhere strictly to recommended preparation and storage guidelines to maintain experimental reliability.

• Dabigatran: Mechanistic Insight and Strategic Guidance for T

  2026-05-08

  This thought-leadership article explores Dabigatran's unique value for translational researchers, bridging mechanistic rationale, assay validation, and the evolving clinical landscape. Drawing from recent advances and APExBIO’s high-purity Dabigatran, we share practical strategies to maximize the impact of thrombin inhibition assays, address experimental challenges, and anticipate future directions in anticoagulation research.

• GSK343: Strategic EZH2 Inhibition for Next-Gen Epigenetic On

  2026-05-07

  This thought-leadership article explores the mechanistic and translational value of GSK343, a potent EZH2 inhibitor, in epigenetic cancer research. Integrating recent mechanistic insights with strategic guidance for translational researchers, we analyze how GSK343 empowers interrogation of PRC2-mediated gene repression, the dynamics of H3K27me3, and emerging cross-talk with DNA repair and telomerase regulation. We compare GSK343's performance against peer tools, highlight workflow optimization, and offer a forward-looking perspective grounded in the latest evidence.

15616 records 1/1042 page Next 12345 下5页 Last page